Status:

COMPLETED

Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions:

Healthy Subjects

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.

Eligibility Criteria

Inclusion

  • Inclusion
  • Men or women of non childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening.
  • Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥50 kg.
  • Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital sign measurements, and 12-lead electrocardiogram (ECG).
  • Serum creatinine level must be less than 1.30 mg/dL. (Normal range: 0.44 to 1.24 mg/dL.)
  • Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.
  • Exclusion
  • Presence or history of any disorder that may prevent the successful completion of the study.
  • Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
  • Any surgical or medical condition that may interfere with the distribution, metabolism, or excretion of the test article.
  • Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.
  • Any history of clinically important cardiac arrhythmias.
  • Familial history of long QT syndrome or unexpected cardiac death.
  • History of drug abuse within 1 year before study day 1.
  • History of alcoholism within 1 year before study day 1.

Exclusion

    Key Trial Info

    Start Date :

    November 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 1 2009

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT00783341

    Start Date

    November 1 2008

    End Date

    February 1 2009

    Last Update

    July 17 2009

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Philadelphia, Pennsylvania, United States, 19428